ESR1 and prostate adenocarcinoma: Regarding the Hormone_ER and AR signatures, these are particularly relevant to hormone-sensitive cancers, such as BRCA and PRAD (prostate adenocarcinoma), given their association with estrogen receptor (ER) and androgen receptor (AR) activity.